Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Skin Neoplasms

ClinicalTrials.gov lists 3,615 trials for Skin Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 217.

MeSH D012878 Neoplasms Neoplasm C04 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 899 Phase 1/2 Phase 1/2 456 Phase 2 Phase 2 944 Phase 2/3 Phase 2/3 25 Phase 3 Phase 3 172 Phase 4 Phase 4 39 Not applicable Not applicable 474 Observational Observational 585 Phase 1 Phase 1 899 Phase 1/2 Phase 1/2 456 Phase 2 Phase 2 944 Phase 2/3 Phase 2/3 25 Phase 3 Phase 3 172 Phase 4 Phase 4 39 Not applicable Not applicable 474 Observational Observational 585

Trials per phase (log scale)

1 more section with rows

562 of the 3,615 trials are tagged with Skin Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Skin Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Skin Neoplasms trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 9 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 208

1990: 1 trials (Observational 1) 1991: 3 trials (Observational 2, Not applicable 1) 1992: 5 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 1) 1993: 4 trials (Observational 1, Phase 3 1, Phase 2 1, Phase 1 1) 1994: 3 trials (Observational 1, Phase 1 2) 1995: 9 trials (Observational 1, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 2) 1996: 15 trials (Observational 3, Phase 3 3, Phase 2 4, Phase 1/2 1, Phase 1 4) 1997: 16 trials (Observational 2, Phase 3 1, Phase 2 4, Phase 1/2 5, Phase 1 4) 1998: 27 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 2 15, Phase 1/2 1, Phase 1 5) 1999: 49 trials (Observational 8, Phase 3 6, Phase 2 21, Phase 1/2 4, Phase 1 10) 2000: 43 trials (Observational 4, Not applicable 5, Phase 3 5, Phase 2 12, Phase 1/2 5, Phase 1 12) 2001: 42 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 15, Phase 1/2 6, Phase 1 15) 2002: 44 trials (Observational 4, Not applicable 2, Phase 3 6, Phase 2 14, Phase 1/2 10, Phase 1 8) 2003: 57 trials (Observational 6, Not applicable 3, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 27, Phase 1/2 8, Phase 1 7) 2004: 84 trials (Observational 8, Not applicable 6, Phase 3 4, Phase 2/3 1, Phase 2 36, Phase 1/2 9, Phase 1 20) 2005: 95 trials (Observational 6, Not applicable 6, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 41, Phase 1/2 14, Phase 1 21) 2006: 93 trials (Observational 13, Not applicable 1, Phase 3 4, Phase 2 34, Phase 1/2 15, Phase 1 26) 2007: 96 trials (Observational 11, Not applicable 7, Phase 4 3, Phase 3 4, Phase 2 37, Phase 1/2 10, Phase 1 24) 2008: 109 trials (Observational 23, Not applicable 6, Phase 4 1, Phase 3 5, Phase 2 35, Phase 1/2 8, Phase 1 31) 2009: 103 trials (Other 1, Observational 15, Not applicable 14, Phase 4 1, Phase 3 4, Phase 2/3 2, Phase 2 29, Phase 1/2 11, Phase 1 26) 2010: 102 trials (Observational 9, Not applicable 6, Phase 3 7, Phase 2 35, Phase 1/2 17, Phase 1 28) 2011: 116 trials (Observational 14, Not applicable 12, Phase 4 1, Phase 3 5, Phase 2/3 2, Phase 2 38, Phase 1/2 9, Phase 1 35) 2012: 113 trials (Observational 13, Not applicable 17, Phase 4 1, Phase 3 7, Phase 2 30, Phase 1/2 11, Phase 1 34) 2013: 146 trials (Observational 25, Not applicable 11, Phase 4 3, Phase 3 8, Phase 2 40, Phase 1/2 14, Phase 1 45) 2014: 138 trials (Observational 22, Not applicable 15, Phase 4 2, Phase 3 4, Phase 2 42, Phase 1/2 21, Phase 1 32) 2015: 175 trials (Observational 27, Not applicable 27, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 38, Phase 1/2 25, Phase 1 46) 2016: 158 trials (Observational 30, Not applicable 19, Phase 3 7, Phase 2 31, Phase 1/2 20, Phase 1 51) 2017: 160 trials (Observational 29, Not applicable 29, Phase 4 1, Phase 3 6, Phase 2/3 2, Phase 2 34, Phase 1/2 22, Phase 1 37) 2018: 180 trials (Observational 28, Not applicable 30, Phase 4 2, Phase 3 6, Phase 2/3 2, Phase 2 33, Phase 1/2 33, Phase 1 46) 2019: 167 trials (Observational 35, Not applicable 23, Phase 4 2, Phase 3 5, Phase 2 40, Phase 1/2 21, Phase 1 41) 2020: 189 trials (Observational 29, Not applicable 35, Phase 4 1, Phase 3 4, Phase 2 39, Phase 1/2 28, Phase 1 53) 2021: 208 trials (Observational 48, Not applicable 34, Phase 3 5, Phase 2/3 2, Phase 2 48, Phase 1/2 24, Phase 1 47) 2022: 203 trials (Observational 39, Not applicable 35, Phase 4 3, Phase 3 11, Phase 2 38, Phase 1/2 23, Phase 1 54) 2023: 163 trials (Observational 27, Not applicable 32, Phase 3 13, Phase 2/3 4, Phase 2 29, Phase 1/2 22, Phase 1 36) 2024: 146 trials (Observational 34, Not applicable 26, Phase 4 2, Phase 3 6, Phase 2/3 2, Phase 2 22, Phase 1/2 18, Phase 1 36) 2025: 168 trials (Observational 42, Not applicable 31, Phase 4 4, Phase 3 5, Phase 2/3 4, Phase 2 28, Phase 1/2 21, Phase 1 33)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 126
2025 168
2024 146
2023 163
2022 203
2021 208
2020 189
2019 167
2018 180
2017 160

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 140 trials starting in 2026 and about 150 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 398 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 2,299 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Skin Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 899
Phase 1/2 456
Phase 2 944
Phase 2/3 25
Phase 3 172
Phase 4 39
Not applicable 474
Observational 585
Expanded access 21

How many Skin Neoplasms trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 87
Recruiting 462
Enrolling by invitation 13
Active, not recruiting 278
Available 5

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Skin Neoplasms trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 217
Bristol-Myers Squibb 91
Novartis Pharmaceuticals 46
Hoffmann-La Roche 45
Pfizer 38

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Skin Neoplasms? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 263
NIVOLUMAB 229
IPILIMUMAB 215
Cytoxan 132
GSK1120212 74

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Low-dose Aldesleukin (Proleukin®) 104
SQ Fludarabine 99
Vermurafenib 64
SOC: Temozolomide 63
Arm 3: Dacarbazine 59

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Skin Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Malignant neoplasm progression 2,001 56
Pyrexia 1,494 169
Pneumonia 1,053 181
Colitis 976 138
Fatigue 895 173

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Skin Neoplasms? (2,262)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Long-Term Outcomes of Oral Propranolol for Facial Infantile Hemangioma. Plastic and reconstructive surgery 2026 Yes
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026 Yes
Nivolumab for Resected Stage III or IV Melanoma at 9 Years. The New England journal of medicine 2026 Yes
Pilot Study of Immediate Lymphatic Reconstruction (ILR) During Lymph Node Dissection for Node-Positive Melanoma: Feasibility, Safety, and Early Outcomes. Journal of surgical oncology 2026 Yes
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. Journal for immunotherapy of cancer 2026 Yes

Showing 5 of 2,262 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages